Trade Alert: Independent Director Of AnaptysBio John Schmid Has Sold Stock
AnaptysBio Independent Director John Schmid recently sold US$1.2 million worth of stock at US$56.11 per share, reducing his total holding by 39%. This was the largest insider sale in the past year for the company, suggesting insiders may be content with the current valuation. While insiders do hold a small percentage of shares, there have been no insider purchases in the last year, and recent selling activity is noted.
Spin-off Imminent At AnaptysBio
AnaptysBio is spinning off First Tracks Biotherapeutics, which is set to debut on the Nasdaq on April 20 under the symbol TRAX with $180 million in cash. The split, approved by Anaptys' board, aims to separate managing royalties from developing new therapeutics. Daniel Faga will lead both companies, with most Anaptys employees moving to First Tracks Bio, while Anaptys focuses on maximizing its royalty streams, notably from Jemperli sales, and existing partnerships.
AnaptysBio (Nasdaq:ANAB) - Stock Analysis
This Simply Wall Street analysis provides a detailed look at AnaptysBio (ANAB), highlighting its undervaluation by 21.9% according to analyst targets, despite currently being unprofitable. The report covers the company's financial health, future growth potential, past performance, recent news including board appointments and price target increases, and insider selling activities, alongside its pipeline of immunology therapeutics.
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $69
J.P. Morgan has reiterated its Buy rating for AnaptysBio (ANAB.US) and set a target price of $69. This indicates a positive outlook from the investment bank regarding the company's stock performance.
ANAB Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for AnaptysBio Inc (ANAB). It highlights a "Strong Buy" overall consensus based on a combination of moving averages and oscillators, with specific indicators like MACD also signaling a Buy. The analysis details key support and resistance levels, moving averages, and momentum indicators like RSI, offering insights into the stock's current technical sentiment.
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20
First Tracks Biotherapeutics, Inc. is set to be spun off from AnaptysBio, Inc., with shares distributed to AnaptysBio shareholders starting April 20, 2026. First Tracks Biotherapeutics will begin trading on Nasdaq under the ticker symbol NASDAQ:TRAX on April 20, 2026, with "when-issued" trading under TRAXV commencing on April 6, 2026. AnaptysBio shareholders as of April 6, 2026, will receive one share of First Tracks Biotherapeutics common stock for each AnaptysBio share held.
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20
First Tracks Biotherapeutics will be spun off from AnaptysBio, with shares distributed to AnaptysBio shareholders at 12:01 a.m. New York City time on April 20, 2026. Shareholders as of April 6, 2026, will receive one share of First Tracks for each AnaptysBio share held. First Tracks Biotherapeutics common stock is expected to begin regular trading on Nasdaq under the ticker symbol TRAX on April 20, 2026.
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock
AnaptysBio (NASDAQ:ANAB) Director John Schmid sold 20,645 shares of the company's stock on March 30th, valued at over $1.15 million, significantly reducing his holdings. Despite this insider selling, the company's stock traded up 4.9% following the announcement of a stock buyback program, and Wall Street analysts have recently raised price targets, maintaining a "Moderate Buy" consensus. The sale represents a 39.50% decrease in Schmid's ownership, yet institutional investors have been increasing their stakes in the biotechnology company.
Director John Schmid Sells 20,645 Shares of AnaptysBio Inc (ANAB)
John Schmid, a Director at AnaptysBio Inc (ANAB), recently sold 20,645 shares of the company, bringing his total ownership to 31,622 shares. This sale is part of a trend for AnaptysBio, which has seen 27 insider sells and no insider buys in the past year. The stock is considered significantly undervalued, trading at a price-to-GF-Value ratio of 0.27, according to GuruFocus.
[Form 4] ANAPTYSBIO, INC Insider Trading Activity
ANAPTYSBIO director John P. Schmid sold 20,645 shares of Common Stock in open-market transactions on March 30, 2026, at weighted average prices between $55.7087 and $57.3989 per share. These sales totaled approximately $1.16 million. Following these transactions, Schmid directly holds 31,622 shares of ANAPTYSBIO Common Stock.
AnaptysBio Director Sold Shares Worth Over $1.1M
John P. Schmid, a Director at AnaptysBio (ANAB), sold shares worth over $1.1 million in three direct transactions on March 30, 2026, at weighted average prices between $55.7087 and $57.3989 per share. Following these sales, Schmid directly owns 31,622 shares of the company's common stock. This information is based on an SEC Form 4 filing.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts
AnaptysBio, Inc. (NASDAQ:ANAB) has received a "Moderate Buy" consensus rating from analysts, with an average one-year price target of $80.10. Several firms like Wedbush and Stifel Nicolaus recently increased their price targets for the company. Despite insider selling, particularly by CEO Daniel Faga, the company reported a strong quarter with EPS and revenue exceeding estimates, although it remains unprofitable.
ANAB: Piper Sandler Raises Price Target to $95.00, Maintains Overweight Rating | ANAB Stock News
Piper Sandler has increased its price target for AnaptysBio (ANAB) from $67.00 to $95.00, while maintaining an Overweight rating. This update, reflecting a 41.79% increase in the target, comes amid several other analyst revisions for ANAB in March 2026. AnaptysBio, a clinical-stage biotechnology company, focuses on developing antibody product candidates for inflammatory and immuno-oncology needs.
Piper Sandler Raises AnaptysBio (NASDAQ:ANAB) Price Target to $95.00
Piper Sandler has increased its price target for AnaptysBio (NASDAQ:ANAB) to $95.00 from $67.00, maintaining an "overweight" rating and suggesting a potential upside of 69% from its current price. This adjustment follows AnaptysBio beating quarterly earnings expectations, reporting an EPS of $1.58 against an estimated $0.89 and revenue of $108.25 million against $87.09 million. The biotechnology company also announced a stock repurchase program of $100 billion, signaling management's belief that its shares are undervalued.
[144] ANAPTYSBIO, INC SEC Filing
This article is an SEC Filing Form 144 for ANAPTYSBIO, INC (ANAB). The filing details a proposed sale of 20,645 shares of common stock with an aggregate market value of $1,158,450.82 by an individual who acquired these shares by exercising them from an issuer on January 13, 2025. The sale is scheduled for March 30, 2026, on NASDAQ, facilitated by Morgan Stanley Smith Barney LLC.
AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus
AnaptysBio is spinning off First Tracks Biotherapeutics, creating a leaner, royalty-focused company while First Tracks pursues antibody development with dedicated funding. AnaptysBio will retain approximately $140-$145 million in cash and investments, focusing on managing existing collaborations, while First Tracks launches with $180 million, including an $80 million private placement. This strategic move aims to reshape AnaptysBio's risk profile, focusing on cash returns and collaboration management, supported by the appointment of a former Royalty Pharma CFO.
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright
HC Wainwright reiterated a "Buy" rating on AnaptysBio (NASDAQ:ANAB) with a $66 target price, indicating a potential upside of nearly 15%. This comes after the biotechnology company reported strong quarterly earnings, beating analyst expectations for both EPS and revenue. Despite insider share sales and negative financial metrics like net margin and return on equity, the company's board has authorized a significant stock buyback program.
AnaptysBio Insider Sold Shares Worth $1,089,199, According to a Recent SEC Filing
An insider at AnaptysBio, Inc. (ANAB) reportedly sold shares valued at $1,089,199, as per a recent SEC filing. The article, published on MarketScreener, highlights this transaction alongside other recent news concerning AnaptysBio, including board appointments, spin-off approvals, and share repurchase plans. The company, a clinical-stage biotechnology firm, focuses on immunology therapeutics and has several drug candidates in various stages of clinical trials.
AnaptysBio (ANAB) price target increased by 21.16% to 79.82
This article reports that the price target for AnaptysBio (ANAB) has been increased by 21.16%, bringing the new target to $79.82.
A Look At AnaptysBio (ANAB) Valuation After Recent Share Price Volatility
AnaptysBio (ANAB) has experienced recent share price volatility, with a sharp one-day decline and a weekly pullback, despite strong year-to-date and one-year returns. The stock is currently trading below analyst targets and its modeled intrinsic value, posing a question about a potential buying opportunity. While its Price-to-Sales (P/S) ratio suggests overvaluation compared to Simply Wall St's fair ratio, a Discounted Cash Flow (DCF) model indicates a significantly higher fair value, creating mixed signals for investors.
Anaptysbio CEO Faga sells $1.1 million in shares
Anaptysbio CEO Daniel Faga sold 16,571 shares of common stock for $1.1 million on March 27, 2026, primarily to cover tax obligations from vested restricted stock units. This transaction follows Faga's acquisition of 34,300 shares two days prior from performance-based units, with the company currently experiencing significant growth and positive analyst attention including increased price targets and a planned spinoff of First Tracks Biotherapeutics.
AnaptysBio (NASDAQ: ANAB) CEO gets PSU grant and sells shares for tax
AnaptysBio CEO Daniel Faga received 34,300 performance-based restricted stock units (PSUs) after performance goals were met on March 25, 2026. Shortly after, on March 27, 2026, Faga sold 17,679 shares of common stock to cover tax withholding obligations associated with the PSU vesting. These sales were non-discretionary and Faga retains a significant stake of 495,965 shares in the company.
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
AnaptysBio (ANAB) is spinning off First Tracks Bio, a clinical-stage biotechnology company focused on antibody therapeutics for autoimmune and inflammatory diseases. First Tracks Bio will launch with $180 million capital and a two-year cash runway, including an $80 million private placement and a one-for-one share distribution to AnaptysBio stockholders. This strategic move aims to refocus AnaptysBio on royalty management while First Tracks Bio drives drug development.
AnaptysBio's First Tracks Raises $80 Million Via $13.81 Private Placement Ahead of Spin-Off
AnaptysBio announced a financing plan for the upcoming spin-off of First Tracks Biotherapeutics, which includes an $80 million private placement at $13.81 per share. The transaction, expected to close after the April 20, 2026 separation, involves the issuance of new and secondary shares, with First Tracks granting registration rights to investors. Concurrently, AnaptysBio terminated its at-the-market Sales Agreement with TD Securities to streamline its capital plans.
AnaptysBio appoints Susannah Gray to board; Dennis Mulroy and Eric Loumeau to Separate
AnaptysBio (ANAB) has appointed Susannah Gray as a Class I director, effective immediately. Concurrently, Dennis Mulroy and Eric Loumeau will separate from the company upon the Spin-Off, expected on April 20, 2026. Mulroy and Loumeau will receive nine months of base pay and COBRA reimbursement, and are expected to enter consulting agreements related to the Spin-Off.
AnaptysBio Inc announced that its subsidiary First Tracks Bio has received approval from the Nasdaq Stock Exchange and will officially initiate "When-Issued Trading" of its shares on April 6, 2026. The trading symbol is set as "Trax".
AnaptysBio Inc.'s subsidiary, First Tracks Bio, has received Nasdaq approval to begin "When-Issued Trading" of its shares on April 6, 2026, under the symbol "Trax". This move signals a significant step in the company's capitalization process, allowing for price discovery before official listing. Professional analysts view such arrangements as an indicator of a company's readiness to enter a substantive stage in the capital market.
AnaptysBio (NASDAQ: ANAB) spins off First Tracks and backs $145M raise
AnaptysBio (NASDAQ: ANAB) is spinning off its drug development assets into a new independent company, First Tracks Biotherapeutics, which will trade on Nasdaq under "TRAX". AnaptysBio shareholders will receive one First Tracks share for each AnaptysBio share held, with the distribution expected on April 20, 2026. First Tracks has secured $145 million in private placement funding, while AnaptysBio will focus on managing royalty streams and has authorized a $100 million stock repurchase plan.
AnaptysBio Announces Spin-Off of First Tracks Biotherapeutics with Distribution Date Set for April 20, 2026
AnaptysBio, Inc. has announced the spin-off of its subsidiary, First Tracks Biotherapeutics, with the distribution date set for April 20, 2026. AnaptysBio shareholders will receive one share of First Tracks Bio common stock for each share of AnaptysBio they own. First Tracks Bio, which will trade on Nasdaq under "TRAX," will focus on developing antibody therapeutics for autoimmune conditions and will launch with an initial cash balance of $180 million.
AnaptysBio Announces Spin-Off of First Tracks Biotherapeutics with Stock Repurchase Plan and Board Update
AnaptysBio is spinning off its biopharma operations into First Tracks Biotherapeutics, with the original company focusing on managing financial collaborations for Jemperli and imsidolimab. The company also announced a $100 million stock repurchase plan and appointed Susannah Gray to its Board of Directors. Post-spin-off, Anaptys will operate with minimal staff and expenses, aiming to return value to shareholders.
Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics
AnaptysBio, Inc. has announced that its Board of Directors has approved the spin-off of First Tracks Biotherapeutics, Inc., with trading expected to begin on April 20, 2026, under the ticker "TRAX". Stockholders of Anaptys will receive one share of First Tracks Bio for every Anaptys share owned. First Tracks Bio will launch with $180 million in cash, funded by Anaptys and a private placement, and will focus on advancing next-generation antibody therapeutics for autoimmune and inflammatory diseases.
First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement
First Tracks Biotherapeutics, the planned spin-off of AnaptysBio, has secured $145 million in commitments through a private placement. This financing, which includes an $80 million direct investment into First Tracks Bio, will provide the company with $180 million in cash and a two-year cash runway upon its expected spin-off on April 20, 2026. The proceeds will be used for general corporate purposes, including the clinical development of ANB033, a CD122 antagonist.
Vanguard reports 0 ANAB shares after internal realignment (ANAB)
The Vanguard Group has filed an Amendment No. 1 to Schedule 13G/A for AnaptysBio Inc (ANAB), reporting zero shares beneficially owned due to an internal realignment. This change is a reporting adjustment, not a market transaction, as Vanguard's subsidiaries will now report their beneficial ownership separately in reliance on SEC Release No. 34-39538. Investors should look to future filings from Vanguard affiliates for detailed holdings.
AnaptysBio (NASDAQ:ANAB) Upgraded to "Hold" at Truist Financial
Truist Financial has upgraded AnaptysBio (NASDAQ:ANAB) to a "hold" rating after the company beat earnings and revenue expectations in its latest quarter, reporting $1.58 EPS against an $0.89 estimate and $108.25M revenue against an $87.09M estimate. Despite the positive earnings surprise, AnaptysBio remains unprofitable with analysts projecting a negative EPS for the current fiscal year. The stock is trading near its 52-week high, and insiders have sold a significant number of shares recently.
UBS raises AnaptysBio stock price target to $90 on pipeline upside
UBS has increased its price target for AnaptysBio (NASDAQ:ANAB) to $90 from $70, maintaining a Buy rating, due to the significant upside potential seen in its pipeline and the CD122 antagonist ANB033. This new target implies a 39% upside, driven by the anticipated performance of its royalty segment, particularly Jemperli sales, and its promising biopharma business. Other analysts also show bullish sentiment, with Truist Securities, Stifel, and H.C. Wainwright revising their price targets following recent positive developments, including AnaptysBio's Q4 2025 revenue exceeding expectations and plans to spin off its biopharma portfolio.
AnaptysBio Hits New 12-Month High
AnaptysBio (NASDAQ:ANAB) reached a new 52-week high of $66.73, closing at $64.78, driven by investor optimism for its pipeline of therapeutic antibody candidates. Analysts from Truist Financial and Wedbush increased their price targets, and the company reported strong Q4 2025 earnings, exceeding analyst estimates. This surge highlights the potential for long-term growth in the clinical-stage biotechnology company that focuses on immunology and inflammation.
How (ANAB) Movements Inform Risk Allocation Models
This article analyzes Anaptysbio Inc. (NASDAQ: ANAB) using AI models to inform risk allocation. It highlights strong sentiment across all horizons supporting an overweight bias despite elevated downside risk and presents three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored to different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Psoriasis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Can-Fite Biopha
DelveInsight's "Psoriasis Pipeline Insight, 2026" report outlines the current clinical development landscape for Psoriasis, identifying over 65 companies working on 75+ treatment therapies. The report details emerging therapies in various trial phases, including Imsidolimab, TAK-279, and Sonelokimab, which are expected to significantly impact the Psoriasis market. Several recent regulatory milestones and clinical trial updates for Psoriasis treatments are highlighted, such as FDA approvals for Tremfya and Otezla for pediatric use, and ongoing trials for other promising drug candidates.
First Light Asset Management LLC Sells 2,549,432 Shares of AnaptysBio, Inc. $ANAB
First Light Asset Management LLC significantly reduced its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 72%, selling over 2.5 million shares, though the stock remains its 13th largest holding. Despite this sale, AnaptysBio has seen positive analyst sentiment with multiple price target increases and a "Moderate Buy" consensus rating, alongside strong Q3 earnings beats and a $100 million share buyback authorization. Other institutional investors, however, increased their holdings in the biotechnology company.
First Light Asset Management Reduces Stake in AnaptysBio
First Light Asset Management LLC has significantly reduced its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 72% in the third quarter of 2026, selling over 2.5 million shares. This move suggests a potential shift in investor sentiment toward the biotechnology company, which focuses on immunology and inflammation therapies. The reduction brings First Light's holding to 3.58% of AnaptysBio's outstanding shares, down from 12.7%.
ANAB SEC Filings - Anaptysbio Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for AnaptysBio Inc. (ANAB) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. It highlights recent filings detailing financial results, investor presentations, a stock repurchase plan, and the exploration of separating the company into two independent entities. The platform also offers AI-powered summaries of these filings to help investors quickly understand key information and strategic decisions concerning ANAB.
Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock
Wedbush has increased its price target for AnaptysBio (NASDAQ:ANAB) stock to $75 from $60, maintaining an "outperform" rating, indicating a potential 21% upside. Despite a mixed market reaction to its latest earnings beat, the company's board authorized a $100 million stock buyback program, while insider sales were noted. AnaptysBio, a clinical-stage biotechnology company, focuses on therapeutic antibody development in immunology and inflammation.
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline
AnaptysBio is moving forward with its plan to separate into two entities: a royalty-holding parent company and a biopharma spin-out called First Tracks Bio. The separation is expected to be completed within 45 days, with the parent company retaining lucrative Jemperli royalty streams and Nolosses (NOLs), while First Tracks Bio will focus on developing ANB033 for celiac disease and eosinophilic esophagitis. AnaptysBio is also involved in ongoing litigation with GSK regarding Jemperli's development, with a decision on a key motion anticipated within 60 days.
ANAB: Biopharma spin-off advances antibody pipeline as royalty business leverages Jemperli growth
AnaptysBio, Inc. (ANAB) is undergoing a major restructuring, splitting into a new biopharma company focused on antibody development and a high-margin royalty business. Key pipeline assets include ANB033 for celiac disease and EoE, with significant data expected in 2024 and 2027, complemented by robust royalty streams from Jemperli. This strategic move aims to advance its antibody programs while leveraging existing successful products.
A Look At AnaptysBio (ANAB) Valuation After Q4 Earnings Turnaround And Jemperli-Linked Milestones
AnaptysBio (ANAB) has reported a significant Q4 earnings turnaround, posting a net income of US$49.61 million, largely driven by collaboration revenues and milestone payments for the cancer drug Jemperli. The company's stock has seen a strong performance, with a 239.11% total shareholder return over the past year. Despite this, a Price-to-Sales ratio of 6.8x suggests mixed valuation, being cheaper than industry peers but higher than its estimated fair P/S of 4.3x, while a DCF model indicates the stock is trading well below its estimated fair value of $457.69 per share.
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Brokerages
AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $73.44. The company recently surpassed quarterly earnings expectations and its board approved a $100 million share buyback program. Despite insider selling, the stock maintains a 33.5% insider ownership.
AnaptysBio, Inc. Experiences Revision in Its Stock Evaluation Amid Market Trends
AnaptysBio, Inc. has seen a revision in its stock evaluation, with its price currently at $57.28, down from a previous close of $60.55. Despite this, the company has delivered an impressive 241.97% return over the past year, significantly outperforming the S&P 500. Technical indicators show mixed signals, with bullish trends on daily moving averages and MACD, but bearish signals on the monthly RSI.
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative
AnaptysBio (ANAB) reported a significant financial turnaround in Q4 FY 2025, with revenues of US$108.2 million and a profit of US$49.6 million, contrasting with previous losses. Despite this strong quarter, the company still shows a trailing twelve-month net loss of US$13.2 million. The article discusses both bullish and bearish perspectives on ANAB's future sustainability, considering its fluctuating revenue, P/S ratio, and discounted cash flow fair value.
Truist Adjusts Price Target on AnaptysBio to $50 From $36, Maintains Hold Rating
Truist has adjusted its price target for AnaptysBio (ANAB) to $50 from the previous $36, while retaining a "Hold" rating on the stock. This adjustment comes amidst other analyst actions on AnaptysBio, including Wedbush raising its price target to $60 and UBS upgrading the stock to "Buy." The company recently reported strong Q4 results, swinging to a profit with revenues exceeding analyst estimates.
AnaptysBio Inc reports results for the quarter ended December 31 - Earnings Summary
AnaptysBio Inc has released its earnings summary for the quarter that ended on December 31. The report, provided by Refinitiv and distributed via Reuters, details the financial performance of the company (ANAB). The article is a brief 1-minute read focusing on analyst earnings.
AnaptysBio stock hits 52-week high at 57.86 USD
AnaptysBio (NASDAQ: ANAB) stock reached a 52-week high of $57.86, reflecting a 246% 1-year total return and strong investor confidence despite potentially being overvalued. The company recently announced plans to spin off its biopharma portfolio, leading to increased price targets from analysts and positive market reactions amidst ongoing litigation and new drug application developments.
